TCRT Alaunos Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: TCRT

Price (delayed)

$1.15

Market cap

$2.92M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.91

Enterprise value

$2.8M

Sign up for free to view scoring metrics ?
Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 25

Alaunos Therapeutics is a T-cell receptor (TCR) cell therapy company powered by its hunTR® (human neoantigen T-cell Receptor) discovery platform. hunTR® enables the rapid identification of wholly owned, proprietary TCRs. ...

Highlights
Alaunos Therapeutics's EPS has increased by 22% YoY and by 10% from the previous quarter
TCRT's net income is up by 2.4% since the previous quarter
The company's quick ratio has shrunk by 95% YoY and by 76% QoQ
TCRT's equity has shrunk by 82% YoY and by 49% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.ziopharm.com
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of TCRT

TCRT stock price

How has the Alaunos Therapeutics stock price performed over time
Intraday
-9.45%
1 week
-10.16%
1 month
-34.66%
1 year
-58.63%
YTD
-64.4%
QTD
-49.12%

Financial performance

How have Alaunos Therapeutics's revenue and profit performed over time
Revenue
$3,000
Gross profit
$3,000
Operating income
-$4.06M
Net income
-$4.01M
Gross margin
100%
Net margin
-133,666.7%
Alaunos Therapeutics's net margin has decreased by 34% YoY but it has increased by 2.4% from the previous quarter
The operating margin has decreased by 34% YoY but it has increased by 2.1% from the previous quarter
The revenue has contracted by 25% YoY
The gross profit has declined by 25% year-on-year

Price vs fundamentals

How does TCRT's price correlate with its fundamentals

Growth

What is Alaunos Therapeutics's growth rate over time

Valuation

What is Alaunos Therapeutics stock price valuation
P/E
N/A
P/B
4.19
P/S
932.15
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
932.52
Alaunos Therapeutics's EPS has increased by 22% YoY and by 10% from the previous quarter
TCRT's equity has shrunk by 82% YoY and by 49% QoQ
The price to book (P/B) is 8% higher than the 5-year quarterly average of 4.3
The price to sales (P/S) is 34% lower than the last 4 quarters average of 1565.8 and 22% lower than the 5-year quarterly average of 1316.1
The revenue has contracted by 25% YoY

Efficiency

How efficient is Alaunos Therapeutics business performance
The return on equity has declined by 40% since the previous quarter and by 38% year-on-year
Alaunos Therapeutics's ROS has decreased by 34% YoY but it has increased by 2.4% from the previous quarter
The company's return on assets fell by 31% YoY and by 29% QoQ
The ROIC fell by 15% YoY and by 6% QoQ

Dividends

What is TCRT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for TCRT.

Financial health

How did Alaunos Therapeutics financials performed over time
The total assets is 75% more than the total liabilities
The company's quick ratio has shrunk by 95% YoY and by 76% QoQ
Alaunos Therapeutics's current ratio has plunged by 78% YoY and by 53% from the previous quarter
Alaunos Therapeutics's debt is 100% less than its equity
TCRT's equity has shrunk by 82% YoY and by 49% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.